Feb 6, 2025 12:29PM Nevro Corp (NVRO) PT Raised to $5.85 at Canaccord Genuity

Feb 6, 2025 09:30AM Globus Medical (GMED) to Acquire Nevro Corp. (NVRO)

Jan 21, 2025 06:00PM MedTech sector outlook for 2025: Truist Securities

Jan 13, 2025 08:35AM Nevro (NVRO) Reports Prelim Q4 Revenue of $105M-$106M

Dec 17, 2024 06:48AM Nevro Corp (NVRO) PT Lowered to $6 at Mizuho

Dec 2, 2024 06:26AM Morgan Stanley Downgrades Nevro Corp (NVRO) to Underweight

Nov 12, 2024 07:51AM Nevro Corp (NVRO) PT Lowered to $6 at Piper Sandler

Nov 12, 2024 07:17AM Nevro Corp (NVRO) PT Raised to $6 at Baird

Nov 12, 2024 06:49AM Nevro Corp (NVRO) PT Lowered to $7 at Canaccord Genuity

Nov 11, 2024 04:08PM Nevro (NVRO) Tops Q3 EPS by 40c, Beats on Revenue; Offers FY24 Revenue Guidance

Oct 15, 2024 06:54AM Nevro Corp (NVRO) PT Lowered to $5 at Baird

Aug 8, 2024 04:41PM Citi Moves to Sidelines Nevro Corp (NVRO), Moves to Neutral, 'uncertainty remains high'

Aug 8, 2024 04:08AM Wolfe Research Upgrades Nevro Corp (NVRO) to Peerperform

Aug 7, 2024 08:14AM Wells Fargo Downgrades Nevro Corp (NVRO) to Underweight

Aug 7, 2024 08:00AM Nevro Corp (NVRO) PT Lowered to $7 at Jefferies

Aug 7, 2024 07:21AM Nevro Corp (NVRO) PT Lowered to $7 at Piper Sandler

Aug 7, 2024 07:04AM Nevro Corp (NVRO) PT Lowered to $7 at RBC Capital

Aug 7, 2024 06:58AM Nevro Corp (NVRO) PT Lowered to $8 at Canaccord Genuity

Aug 7, 2024 02:21AM JMP Securities Downgrades Nevro Corp (NVRO) to Market Perform

Aug 7, 2024 02:21AM JPMorgan Downgrades Nevro Corp (NVRO) to Underweight

Aug 6, 2024 05:01PM Nevro (NVRO) Tops Q2 EPS by 17c, provides guidance

Jul 16, 2024 07:46AM Nevro Corp (NVRO) PT Lowered to $10 at Truist Securities

Jul 16, 2024 06:54AM Nevro Corp (NVRO) PT Lowered to $11 at Baird